Nutex Health Inc.
NUTX Nasdaq· Services-Business Services, Nec
Last close · Oct 23, 2026
$209.59
KIRA · Stoqly’s AI analyst, in plain words
- Nutex Health Inc. had $875M of revenue in fiscal 2025, up 82.4% on the year before. Over five years, revenue changed +26.1% a year on average.
- Its operating margin was 31.5%, up 4.3 pts: of every 100 in sales, about 31 is left after running the business.
- Nutex Health Inc. made $70.8M of net profit in fiscal 2025.
- Free cash flow was $246M in fiscal 2025, 28.1% of revenue.
- Nutex Health Inc. returned $5.0M to shareholders in fiscal 2025, 2% of free cash flow. The diluted share count rose 23.0%.
- Nutex Health Inc. has $143M more cash than debt.
Market cap
$1.5B
P/E
8.1x
Revenue
$875M
Net income
$70.8M
Free cash flow
$246M
Operating margin
31.5%
Nutex Health Inc. in 30 seconds · fiscal 2025
Are sales growing?
+82.4%
Yes. Sales grew 82.4% last year.
Does it make a profit?
8.1%
A little. It keeps 8.1% of every sale as profit.
Does profit turn into cash?
28.1%
Yes. 28.1% of sales ends up as free cash.
Is debt under control?
Net cash
Yes. It has more cash than debt.
How healthy are the accounts?
7 / 9
Solid. It passes 7 of 9 health tests.
How is the share priced?
8.1x
One share costs 8.1 times its yearly profit per share.
What Nutex Health Inc. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Mar 5, 2026
- Legal name
- Nutex Health Inc.
- CIK
- 0001479681
Nutex Health Inc. · NUTX
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $332M | $219M | $248M | $480M | $875M |
| Revenue growth | 21.0% | −33.9% | 12.9% | 93.8% | 82.4% |
| Net interest income | −$6.0M | — | — | — | — |
| Gross margin | 54.1% | 7.0% | 14.0% | 40.9% | 50.8% |
| Operating margin | 51.4% | −185.4% | −12.8% | 27.2% | 31.5% |
| Net income | $133M | −$425M | −$45.8M | $52.1M | $70.8M |
| Net margin | 40.0% | −193.7% | −18.5% | 10.9% | 8.1% |
| Diluted EPS | $0.22 | −$100.36 | −$10.39 | $9.69 | $10.48 |
| Cash | |||||
| Cash from operations | $173M | $50.6M | $1.3M | $23.2M | $248M |
| Capital expenditure | $36.9M | $14.6M | $9.5M | $2.3M | $2.5M |
| Free cash flow | $137M | $36.0M | −$8.2M | $20.8M | $246M |
| FCF margin | 41.2% | 16.4% | −3.3% | 4.3% | 28.1% |
| Share buybacks | — | — | $0.0M | $0.0M | $5.0M |
| Share count change | — | — | 4.2% | 24.6% | 23.0% |
| Debt and strength | |||||
| Cash and short-term investments | $36.1M | $34.3M | $22.0M | $40.6M | $186M |
| Debt incl. finance leases | $168M | $35.6M | $37.1M | $36.9M | $42.5M |
| Shareholders' equity | $115M | $95.9M | $61.5M | $132M | $329M |
| Net debt / EBITDA | 0.7x | — | — | −0.0x | −0.5x |
| Current ratio | 4.1x | 1.8x | 1.6x | 1.9x | 3.4x |
| Interest coverage | 27.5x | −32.6x | −1.9x | 6.6x | 12.4x |
| Returns and quality | |||||
| Return on capital | 68.6% | −330.4% | −32.8% | 87.7% | 109.0% |
| Return on equity | 233.6% | −403.6% | −58.2% | 53.7% | 30.7% |
| Return on tangible equity | 12.1% | −736.7% | −191.8% | 50.6% | 24.1% |
| Piotroski F-score | 4 | 3 | 5 | 7 | 7 |
| Altman Z'' | 6.3 | −8.1 | −3.1 | 1.2 | 4.4 |
Insiders bought, 12 months
$0.1M
5 insiders
Insiders sold, 12 months
$0.0M
1 insider
Of sales under plans
0%
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Nutex Health Inc. · NUTX
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $209.59 a share, the company is worth $1.5B: 8.1 times its earnings of the last four quarters.
Source: SEC EDGAR XBRL filings (CIK 0001479681). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.